Sylvia Hartl

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial

Thomas Köhnlein, Wolfram Windisch, Dieter Köhler et al. · The Lancet Respiratory Medicine · 2014 · 793 citations

Asthma, Advanced Lung Disease, Ventilation +4

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Differences in content and organisational aspects of pulmonary rehabilitation programmes

Martijn A. Spruit, Fábio Pitta, Chris Garvey et al. · European Respiratory Journal · 2013 · 295 citations · Full text

Pulmonary Care, Advanced Lung Disease, Disability +18

Incidence and outcome of weaning from mechanical ventilation according to new categories

G-C. Funk, Shilo Anders, M.-K. Breyer et al. · European Respiratory Journal · 2009 · 270 citations · Full text

Asthma, Pulmonary Care, Critical Care Medicine +17